AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17013635
Drug: Acute tryptophan
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute tryptophan depletion (capsules containing an amino acid mixture specifically lacking tryptophan)
Trial: 11045790
Drug: fenretinide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenretinide (200 mg day p.o. for 24 months)
Trial: 25869467
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic and steroid combination (ofloxacin 0.26% and dexamethasone 0.053% nasal drops) for 10 days, administered intranasally (5 drops in each nostril/8 hours)
Trial: 25869467
Drug: Oral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotic alone (amoxicillin 90 mg/kg)
Trial: 21612429
Drug: Guarana 50
RxNorm normalized name: GUARANA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guarana 50 mg by mouth twice daily
Trial: 19824119
Drug: Intramuscular meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular meperidine (n = 30)
Trial: 16805714
Drug: Combination regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimens with chemotherapy and/or biological therapy
Trial: 8167785
Drug: Placebo/control treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/control treatment
Trial: 2964981
Drug: Intensified conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified conventional treatment (ICT) using the NovoPen
Trial: 30301187
Drug: SOC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC plus vaccination with Audencel (weekly intranodal application in weeks 7 to 10, followed by monthly intervals)
Trial: 18637156
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg of imidafenacin/day
Trial: 18637156
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg of imidafenacin/day
Trial: 18637156
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of imidafenacin/day
Trial: 17436825
Drug: ER-minocycline 1
RxNorm normalized name: meclocycline
DrugBank: Meclocycline (DB13092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ER-minocycline 1 mg/kg
Trial: 17436825
Drug: ER-minocycline 2
RxNorm normalized name: meclocycline
DrugBank: Meclocycline (DB13092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ER-minocycline 2 mg/kg
Trial: 17436825
Drug: ER-minocycline 3
RxNorm normalized name: meclocycline
DrugBank: Meclocycline (DB13092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ER-minocycline 3 mg/kg
Trial: 8798927
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of tramadol (Protradon and Tramal)
Trial: 1335441
Drug: GU‐052 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GU‐052 (3 x 4 g daily)
Trial: 1335441
Drug: Glucotard (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucotard (3 x 5 g daily)
Trial: 6693703
Drug: Clinical pharmacists
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacists prescribing drug therapy
Trial: 24679469
Drug: Guselkumab 10
RxNorm normalized name: guselkumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 10 mg
Trial: 24679469
Drug: Guselkumab 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 30 mg
Trial: 24679469
Drug: Guselkumab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 300 mg
Trial: 24679469
Drug: Guselkumab (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab (combined doses)
Trial: 19178747
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise training (walking program to achieve the same weekly physical activity for six months)
Trial: 17184435
Drug: Thiopental 5
RxNorm normalized name: thiopental 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 5 mg x kg(‐1) i.v. for children up to 3 years; 2.5 mg x kg(‐1) i.v. rescue boluses if needed.
Trial: 17184435
Drug: Propofol 1-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1-1.5 mg x kg(‐1) i.v. for children over 3 years; maintained with 0.1-0.15 mg x kg(‐1) x min(‐1) continuous i.v. infusion, increased if needed.
Trial: 9394873
Drug: Tricyclic Antidepressant
RxNorm normalized name: Tricyclic antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic Antidepressant (TCA)
Trial: 24625229
Drug: Bioengineered hyaluronic
RxNorm normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioengineered hyaluronic acid (BioHA, 1% sodium hyaluronate) intra-articular injections
Trial: 24625229
Drug: Conventional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional care (CC) including NSAIDs and analgesics
Trial: 14565628
Drug: Flite Tabs
RxNorm normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flite Tabs (150 mg pinokinase)
Trial: 8828022
Drug: Ebastine 10mg
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 10mg once daily in the morning
Trial: 8828022
Drug: Ebastine 20mg
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 20mg once daily in the morning
Trial: 8828022
Drug: Ebastine 10mg
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 10mg once daily in the evening
Trial: 8828022
Drug: Ebastine 10mg
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 10mg or 20mg once daily (4-month study)
Trial: 6360688
Drug: Diltiazem (D)
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem (D) 282 +/- 102 mg/day
Trial: 6360688
Drug: Propranolol (P)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (P) 158 +/- 81 mg/day
Trial: 27016862
Drug: Standardized smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized smoking cessation intervention (physician advice, nicotine replacement therapy, referral to counseling)
Trial: 19850697
Drug: Randomized treatments
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized treatments (n-3 polyunsaturated fatty acids or rosuvastatin)
Trial: 18069598
Drug: Angiotensin AT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin AT1 receptor antagonists
Trial: 12172536
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 6 or more risk characteristics
Trial: 10023611
Drug: Therapeutic community
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic community treatment
Trial: 7788898
Drug: Praziquantel at
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel at 180 mg/kg bwt for three days
Trial: 7788898
Drug: Albendazole at
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole at 90 mg/kg bwt for three days
Trial: 7788898
Drug: Praziquantel at
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel at 90 mg/kg bwt plus Albendazole at 45 mg/kg for three days
Trial: 7070229
Drug: 0.005 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005 mg/kg of apomorphine
Trial: 24875890
Drug: Dexmedetomidine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 2 μg/kg
Trial: 19398463
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (1 microg/kg every 4 hours)
Trial: 12591004
Drug: Entrox-coated ALA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entrox-coated ALA formulation (6g dose)
Trial: 12591004
Drug: Non-coated ALA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-coated ALA formulation (6g dose)
Trial: 11194781
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with beta‐agonist and anticholinergic bronchodilators
Trial: 8858633
Drug: Intraoperative mitomycin-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative mitomycin-C (0.1 mg/ml applied for 3 minutes)
Trial: 8858633
Drug: Topical mitomycin-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mitomycin-C (0.05 mg/ml drops applied for 2 weeks postoperatively)
Trial: 1518497
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral antibiotic therapy (non-quinolone)
Trial: 6205676
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of 0.1% solution of bleomycin sulphate in normal saline
Trial: 24084539
Drug: Mifepristone followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone followed by misoprostol (800 micrograms vaginally followed by 400 micrograms orally every 3 hours, max 4 doses)
Trial: 21122577
Drug: 20mg prednisone
RxNorm normalized name: prednisone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg prednisone daily for two weeks prior to surveillance colonoscopy
Trial: 8877677
Drug: Atorvastatin capsules
RxNorm normalized name: atorvastatin Oral Capsule
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin capsules (0.5 to 120 mg)
Trial: 8877677
Drug: Atorvastatin solution
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin solution (0.5 to 120 mg)
Trial: 24214189
Drug: Topiroxostat 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiroxostat 180 mg
Trial: 18003554
Drug: L-dopa administration
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa administration
Trial: 18003554
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of STN stimulation and L-dopa
Trial: 11022827
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg daily for 3 weeks
Trial: 9002496
Drug: Acadesine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acadesine (0.1 mg·kg‐1·min‐1; intravenous infusion for 7 continuous hours and via the cardioplegia solution)
Trial: 8455236
Drug: Single intravesical
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravesical instillation of 80 mg epirubicin
Trial: 30679293
Drug: internet-delivered cognitive-behavioural
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-delivered cognitive-behavioural therapy (internet-CBT)
Trial: 23522518
Drug: Caregiver understanding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver understanding and comfort with administering pain medications.
Trial: 15447897
Drug: Iron (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (20 mg)
Trial: 15447897
Drug: Zinc (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (20 mg)
Trial: 22058086
Drug: Silymarin therapy
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin therapy
Trial: 22801961
Drug: Lintuzumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lintuzumab (600 mg) plus low-dose cytarabine (20 mg subcutaneously twice daily)
Trial: 22801961
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus low-dose cytarabine (20 mg subcutaneously twice daily)
Trial: 22801961
Drug: Lintuzumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lintuzumab (600 mg)
Trial: 22189801
Drug: Nutritional intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional intervention (dietetic supplement during dialysis containing 355 kcal)
Trial: 8850177
Drug: 0.65 g
RxNorm normalized name: Tumil-K 2 MEQ/0.65 GM Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.65 g of n‐3 PUFA for 12 weeks
Trial: 1378116
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ibopamine
Trial: 27358643
Drug: Intrathecal 2
RxNorm normalized name: ZICONOTIDE 25MCG/ML INJ INTRATHECAL 20ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 2 mg midazolam
Trial: 21073703
Drug: Additional physiotherapy
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional physiotherapy and occupational therapy services on Saturday
Trial: 21073703
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care physiotherapy and occupational therapy from Monday to Friday
Trial: 19260323
Drug: Puerarin with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin with aspirin
Trial: 15870588
Drug: Polestriding exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polestriding exercise training (24-week program, 3 times weekly)
Trial: 10825304
Drug: Beta-blockers (esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (esmolol infusions on the day of surgery and metoprolol for the next 48 hours)
Trial: 6367018
Drug: Allogeneic bone
RxNorm normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic bone marrow graft with high dose cyclophosphamide and total body irradiation (8 Gray)
Trial: 30335070
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of cortexin
Trial: 30335070
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of cortexin
Trial: 28091501
Drug: Rac-hopantenic acid
RxNorm normalized name: rac-lactic acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rac-hopantenic acid (pantogam activ) at a daily dose of 1200 mg for 21 days
Trial: 28091501
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with SSRI antidepressants
Trial: 25476698
Drug: Acupuncture (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (daily for nine consecutive days on five points, six cycles for a total of 60 days)
Trial: 20538079
Drug: Intravenous Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Cefazolin
Trial: 8783774
Drug: Remikiren 600
RxNorm normalized name: remikiren
DrugBank: Remikiren (DB00212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren 600 mg orally for 8 days
Trial: 8783774
Drug: Remikiren 600
RxNorm normalized name: remikiren
DrugBank: Remikiren (DB00212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren 600 mg with hydrochlorothiazide 12.5 mg or 25 mg for last 4 days
Trial: 8783774
Drug: Remikiren 600
RxNorm normalized name: remikiren
DrugBank: Remikiren (DB00212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren 600 mg orally
Trial: 30284586
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg hydromorphone (2 mL)
Trial: 30284586
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL normal saline intravenously
Trial: 26581682
Drug: Cocoa beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa beverage containing 320 mg total cocoa flavanols/day
Trial: 25876348
Drug: Moving cupping
RxNorm normalized name: chondroitin sulfates
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moving cupping therapy combined with autohemotherapy with acupoint injection (1 mL at each acupoint, once every 3 days)
Trial: 25876348
Drug: Cetirizine tablets
RxNorm normalized name: cetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine tablets (10 mg once daily) and compound dexamethasone acetate cream (once to twice daily)
Trial: 25876348
Drug: Moving cupping
RxNorm normalized name: chondroitin sulfates
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moving cupping therapy combined with autohemotherapy with acupoint injection
Trial: 25876348
Drug: Cetirizine tablets
RxNorm normalized name: cetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine tablets and compound dexamethasone acetate cream
Trial: 20140214
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg FMP2.1 in 0.1 mL AS02(A)
Trial: 20140214
Drug: 25 microg
RxNorm normalized name: Digoxin 125 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 microg FMP2.1 in 0.25 mL AS02(A)
Trial: 20140214
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg FMP2.1 in 0.5 mL AS02(A)
Trial: 20140214
Drug: All malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All malaria vaccine groups
Trial: 1970633
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g DS implant
Trial: 1970633
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) implants
Trial: 393242
Drug: Transdermal therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal therapeutic system scopolamine (TTS-scopolamine)
Trial: 393242
Drug: Oral dimenhydrinate
RxNorm normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dimenhydrinate
Trial: 31048871
Drug: Paromomycin-gentamicin topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin-gentamicin topical cream
Trial: 31048871
Drug: Paromomycin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin alone topical cream
Trial: 18781486
Drug: Soy (52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy (52 g of soy protein containing 112 mg of isoflavones)
Trial: 12904084
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with dendritic cells
Trial: 11214425
Drug: Epoetin-alpha 10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-alpha 10,000 UI twice a week and 525 mg ferrous sulphate 3 times a day
Trial: 11214425
Drug: 525 mg
RxNorm normalized name: psyllium 525 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 525 mg ferrous sulphate three times a day per os for 3 weeks
Trial: 9414541
Drug: Radical treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical treatments (radical prostatectomy, radical radiotherapy)
Trial: 9414541
Drug: Conservative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative management (monitoring and treatment of symptoms)
Trial: 8017473
Drug: Fluvastatin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 10 to 40 mg/day
Trial: 2783678
Drug: Endoscopic sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic sclerotherapy plus oral propranolol
Trial: 2783678
Drug: Transhepatic sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transhepatic sclerotherapy plus oral propranolol
Trial: 781848
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate ointment; treated with active drug for three weeks
Trial: 23819224
Drug: Comprehensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive therapy (qi pathway intervention and spinal adjustment)
Trial: 23819224
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (acupuncture and Tuina)
Trial: 22568666
Drug: Alkaline formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkaline formulation of human albumin (pH 10)
Trial: 22568666
Drug: Neutral formulation
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral formulation of human albumin (pH 7.4)
Trial: 22568666
Drug: All injections
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All injections (both formulations)
Trial: 15969309
Drug: Intranasal phototherapy
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal phototherapy (3 times a week for 3 weeks)
Trial: 12028307
Drug: Control teeth
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control teeth (not exposed to demineralizing solution)
Trial: 9809500
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide aqueous suspension (256 microg once daily)